We have completed a Phase I clinical trial of IGF-methotrexate (IGF-MTX) in patients with mixed solid tumors and lymphoma. The results show the following:
See additional information here: https://clinicaltrials.gov/ct2/show/NCT02045368
We are currently conducting a Phase 1a/2b clinical trial of IGF-MTX in myelodysplastic syndrome at the Mayo Clinic: https://clinicaltrials.gov/ct2/show/NCT03175978
We plan to open a Phase I clinical trial of a different agent to treat ovarian cancer.